Insider Sales at Acrivon: CEO & COO Sell Shares, Yet Market Confidence Persists

Insider Activity Highlights

On 18 August 2026, Acrivon Therapeutics, Inc. reported a series of insider transactions involving senior management. Chief Accounting Officer Katharine Peterson sold 101 shares of the company’s common stock at an average price of $2.01, a transaction that was executed to satisfy the automatic tax withholding on vested restricted‑stock‑unit (RSU) holdings. The sale occurred at a price slightly below the close of $2.39, contributing a modest $0.08 decline in the share price. Although the volume of shares sold represents a negligible percentage of the company’s $96 million market capitalization, the timing and the simultaneous activity by several executives, coupled with a 294 % increase in social‑media discussion, have attracted heightened investor scrutiny.

Implications for Investors

Peterson’s sale aligns with a broader pattern of insider divestitures observed during the same regulatory filing window. The President‑CEO, Peter Blume‑Jensen, disposed of 1,713 shares, while Chief Legal Officer Mary Miller sold 185 shares. Historically, Acrivon’s insiders have alternated between substantial purchases—often tied to option vesting—and modest sales that reflect routine tax‑withholding or portfolio rebalancing. The current tranche of sales does not appear to signal an abrupt loss of confidence; rather, it reflects the normal exercise of vesting rights.

The spike in social‑media chatter may amplify perceptions of volatility and exert additional pressure on the stock, which has already posted an 18.92 % weekly gain. For investors, the key takeaway is that the company’s leadership remains actively invested. After the August sale, Peterson holds 18,033 shares, equivalent to approximately 0.19 % of outstanding shares. The recent sales are likely to be absorbed by the market without a sustained impact on valuation.

What the Trend Means for Acrivon’s Future

Acrivon’s insiders have historically maintained a strong net long position. Peterson’s most recent purchase on 20 May 2026 added 14,227 shares, bringing her stake to 18,134 shares. The 31,900‑share option purchase in March 2026 further reinforced her commitment. This pattern—periodic buying during option vesting and modest selling for tax purposes—suggests confidence in the company’s clinical pipeline. The current sales do not coincide with any adverse news concerning the oncology platform or clinical trial milestones. As a clinical‑stage company with a 52‑week high of $3.56, Acrivon’s share price remains within a realistic range for a firm advancing precision proteomics diagnostics. Continued insider buying could serve as a bullish signal, whereas a sustained trend of outsized sales might warrant closer scrutiny.

Profile: Katharine Peterson, Chief Accounting Officer

Katharine Peterson has been a central figure in Acrivon’s financial stewardship since her appointment in early 2025. Over the past year, she has executed a series of transactions that mirror the typical cycle of RSU vesting and option exercise:

• Option Activity: In March 2026, Peterson exercised 31,900 RSUs, a sizable move that reflects the company’s vesting schedule and reinforces her long‑term alignment with shareholders.
• Regular Sales: Her most recent sales—99 shares at $1.92 in May, 116 shares at $1.63 in February, and the 101‑share tax‑withholding sale in August—are all modest and consistent with routine tax‑withholding or portfolio rebalancing.
• Net Position: After the August sale, Peterson holds 18,033 shares, an increase from the 18,134 shares held after May’s purchase, indicating a net long stance of approximately 18,000 shares across all transactions.

Peterson’s trading pattern demonstrates a disciplined approach: she buys during vesting, sells only to cover tax liabilities, and maintains a significant minority stake. This behavior aligns with the expectations for a Chief Accounting Officer tasked with ensuring financial transparency and stewardship for shareholders.

Conclusion

The 18 August sale is a routine tax‑withholding event that occurs against a backdrop of heightened social‑media interest and a cluster of insider sales by senior executives. Investors should view Peterson’s transaction as part of a broader, historically bullish insider activity profile. The company’s continued pipeline progress, combined with a stable insider ownership base, suggests that Acrivon’s valuation will likely remain anchored around its current $2.39 close, barring any material adverse developments in its oncology platform or regulatory approvals.